Endotoxin augments hemodynamic and metabolic effects of formyl-methionyl-leucyl-phenylalanine (FMLP) in rabbits

In Vivo

Volumn 21, Issue 1, 2007, Pages 81-88

  Tzanela, Marinella ^a,c   Orfanos, Stylianos ^b   McCormick, James R ^a,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Chemotactic factors; Endotoxin; Hypotension; Septic shock

Indexed keywords

BICARBONATE; ESCHERICHIA COLI ENDOTOXIN; FORMYLMETHIONYLLEUCYLPHENYLALANINE; LACTIC ACID;

ARTICLE; BICARBONATE BLOOD LEVEL; CONTROLLED STUDY; HEMODYNAMICS; HYPERVENTILATION; HYPOTENSION; LACTIC ACIDEMIA; LACTIC ACIDOSIS; MEAN ARTERIAL PRESSURE; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; RABBIT; SEPTIC SHOCK; THROMBOCYTOPENIA;

EID: 33847677289     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Ahmed N and Christou N: Systemic inflammatory response syndrome: interactions between cells and the endothelium. Shock 6: S39-42, 1996.
2. Klosterhalfen B, Horstmann-Juhgemann K, Vogel P et al: Time course of various inflammatory mediators during recurrent endotoxemia. Biochem Pharmacol 43: 2103-2109, 1992.
3. Ulloa L and Tracey KJ: The "cytokine profile": a code for sepsis. Trends Mol Med 11: 56-63, 2005.
4. Yuo A, Kitagawa S, Kasahara T et al: Stimulation and priming of human neutrophils by interleukin-8: cooperation with tumor necrosis factor and colony-stimulating factors. Blood 78: 2708-2714, 1991.
5. Gougerot Podicalo MA, Elbim C and Chollet Martin S: Modulation of the oxidative burst of human neutrophils by pro- and anti-inflammatory cytokines. Pathol Biol Paris 44: 36-41, 1996.
6. Van den Berghe G, de Zegher F and Bouìllon R: Acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab 83: 1827-1834, 1998.
7. Sprung CL, Schultz DR, Marcial E et al: Complement activation in septic shock patients. Crit Care Med 14: 525-528, 1986.
8. Corrigan JJ, Ray WL and May N: Changes in the blood coagulation system associated with septicemia. N Engl J Med 279: 851-856, 1968.
9. Becker EL: The formylpeptide receptor of the neutrophil. A search and conserve operation. Am J Pathol 129: 16-24, 1987.
10. Marasco WA, Phan SH, Krutzch H et al: Purification and indetification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by escherichia coli. J Biol Chem 259: 5430-5439, 1984.
11. Sahagun-Ruiz A, Colla JS, Juhn J, Gao JL, Murphy PM and McDermott DH: Contrasting evolution of the human leukocyte N-formylpeptide receptor subtypes FPR and FPRL1R. Genes Immun 2: 335-342, 2001.
12. Le Y, Iribarren P, Zhou Y, Gong W, Hu J, Zhang X and Wang JM: Silencing the formylpeptide receptor FPR by short-interfering RNA. Mol Pharmacol 66: 1022-1028, 2004.
13. Dalpiaz A, Spisani S, Biondi C, Fabbri E, Nalli M and Ferretti ME: Studies on human neutrophil biological functions by means of formyl-peptide receptor agonists and antagonists. Curr Drug Targets Immune Endocr Metabol Disord 3: 33-42, 2003.
14. Tiffany HL, Lavigne MC, Cui YH, Wang JM, Leto TL, Gao JL and Murphy PM: Amyloid-beta induces chemotaxis and oxidant stress by acting at formylpeptide receptor 2, a G protein-coupled receptor expressed in phagocytes and brain. J Biol Chem 276: 23645-23652, 2001.
15. Saito H, Matsuo M, Naminohira S et al: Effect of N-formyl-L-methionyl-L-leucyl-L-phenylalanine and its analogues on blood pressure. J Pharm Dyn 6: 141-144, 1983.
16. Jonsson M, Tzanela M and Kolbeck RC: Hemodynamic and metabolic effects of intravenous formyl-methionyl-leucyl-phenylalanine (FMLP) in rabbits. In Vivo 11: 133-140, 1997.
17. Bone RC: Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 24: 163-172, 1996.
18. Wichterman KA, Baue AE and Chaudry IH: Sepsis and septic shock - a review of laboratory models and a proposal. J Surg Res 29: 189-201, 1980.
19. Fehr J, Dahinden C and Russi R: Formylated chemotactic peptides can mimic the secondary, provoking endotoxin injection in the generalized Shwartzman reaction. J Infec Dis 150: 160-161, 1984.
20. Goldman DW, Enkel H, Gifford LA et al: Lipopolysaccharide modulates receptors for leukotriene B4, C5a, and formyl-methionyl-leucyl-phenylalanine on rabbit polymorphonuclear leukocytes. J Immunol 137: 1971-1976, 1986.
21. Smedly LA, Tonnesen MG, Sandhaus RA et al: Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase. J Clin Invest 77: 1233-1243, 1986.
22. Voelkel NF, Czartolomna J, Simpson J et al: FMLP causes eicosanoid-dependent vasoconstriction and edema in lungs from endotoxin-primed rats. Am Rev Respir Dis 145: 701-711, 1992.
23. Snyderman R and Fudman EJ: Demonstration of a chemotactic factor receptor on macrophages. J Immunol 124: 2754-2757, 1980.
24. Doherty DE, Haslett C, Tonnesen MG et al: Human monocyte adherence: A primary effect of chemotactic factors on the monocyte to stimulate adherence to human endothelium. J Immunol 138: 1762-1771, 1987.
25. Selvatici R, Falzarano S, Traniello S, Pagani Zecchini G and Spisani S: Formylpeptides trigger selective molecular pathways that are required in the physiological functions of human neutrophils. Cell Signal 15: 377-383, 2003.
26. Miyake Y, Yasuhara T, Fuikui K et al: Purification and characterization of neutrophil chemotactic factors of streptococcus sanguis. Biochem Biophys Acta 758: 181-186, 1983.
27. Rot A, Henderson LE, Coperland TD et al: A series of six ligands for the human formyl peptide receptor: Tetrapeptides with high chemotactic potency and efficacy. Proc Natl Acad Sci USA 84: 7967-7971, 1987.
28. Meyer J, Traber LD, Nelson S et al: Reversal of hyperdynamic response to continuous endotoxin administration by inhibition of NO synthesis. J Appl Physiol 73: 324-328, 1992.
29. Thiemermann C and Van J: Inhibition of Nitric Oxide Synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharm 182: 591-595, 1990.
30. Stetson CA: Studies on the mechanism of the Shwartzman phenomenon. Certain factors involved in the production of the local hemorrhagic necrosis. J Exp Med 93: 489-504, 1951.
31. Stewart AG, Dubbin PN, Harris T et al: Platelet activating factor may act as a second messenger in the release of eicosanoids and superoxide anions from leukocytes and endothelial cells. Proc Natl Acad Sci USA 87: 3215-3219, 1990.
32. Qi M and Jones SB: Contribution of platelet activating factor to hemodynamic and sympathetic responses to bacterial endotoxin in conscious rats. Circ Shock 32: 153-163, 1990.
33. Bellomo R, Kellum JA and Pinsky MR: Transvisceral lactate fluxes during endotoxemia. Chest 110: 198-204, 1996.
34. Johnson A, Hocking DC and Ferro TJ: Tumor necrosis factor-alpha primes pulmonary hemodynamic response to N-formyl-L-methionyl-L-leucyl-L-phenylalanine. Am J Physiol 261: H996-1004, 1991.
35. Mitsuhashi H, Asano S, Nonaka T et al: Potency of truncated secretory leukoprotease inhibitor assesed in acute lung injury models in hamsters. J Pharmacol Exp Ther 282: 1005-1010, 1997.
36. Atkinson YH, Marasco WA, Lopez AF et al: Recombinant human tumor necrosis factor-α. Regulation of N-formyl-methionyl-leucyl-phenylalanine receptor affinity and function on human neutrophils. J Clin Invest 81: 759-765, 1988.
37. Cassatella MA, Bazzoni F, Ceska M et al: IL-8 production by human polymorphonuclear leukocytes. The chemoattractant formyl-methionyl-leucyl-phenylalanine induces the gene expression and release of IL-8 through a pertussis toxin-sensitive pathway. J Immunol 148: 3216-3220, 1992.
38. Hojman H, Lounsbury D, Harris H et al: Immunodepressive effects of LPS on monocyte CD14 in vivo. J Surg Res 69: 7-10, 1997.